Cancer Research and Treatment

Original Articles

Genitourinary cancer

Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan: Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak; Cancer Res Treat. 2024;56(2):634-641. Published online December 5, 2023; DOI: https://doi.org/10.4143/crt.2023.848

Abstract PDF Supplementary Material PubReader ePub

Purpose
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

Citations

Citations to this article as recorded by

ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock
Materials Today Bio.2024; : 101424. CrossRef

3,327 View
129 Download
1 Crossref

Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea: Sahyun Pak, Dalsan You, In Gab Jeong, Dong-Eun Lee, Sung Han Kim, Jae Young Joung, Kang-Hyun Lee, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn; Cancer Res Treat. 2020;52(4):1242-1250. Published online July 3, 2020; DOI: https://doi.org/10.4143/crt.2020.286

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to examine the causes of death in Korean patients who underwent radical prostatectomy for prostate cancer and investigate the relationship between comorbidity and mortality.
Materials and Methods
We conducted a retrospective multicenter cohort study including 4,064 consecutive patients who had prostate cancer and underwent radical prostatectomy between January 1998 and June 2013. The primary endpoint of this study was all-cause mortality, and the secondary endpoints were cancer-specific mortality (CSM) and other-cause mortality (OCM). Charlson comorbidity index (CCI) was calculated to assess the comorbidities of each patient.
Results
Of 4,064 patients, 446 (11.0%) died during follow-up. The cause of death was prostate cancer in 132 patients (29.6%), other cancers in 121 patients (27.1%), and vascular disease in 57 patients (12.8%) in our cohort. The overall 10-year CSM rate was lower than the OCM rate (4.6% vs. 10.5%). The 10-year CSM rate was lower than the OCM rate in low- to intermediate-risk group patients (1.2% vs. 10.6%), whereas they were similar in high-risk group patients (11.8% vs. 10.1%). In the multivariable analysis, CCI was independently associated with all-cause mortality after radical prostatectomy, regardless of age and pathologic features.
Conclusion
Death from prostate cancer was rare in Korean men who underwent radical prostatectomy. Clinicians should be aware of the possibility of overtreatment of low-risk prostate cancer in men with significant comorbidity. Our findings may help to facilitate counseling and plan management in this patient group.

7,021 View
111 Download
3 Web of Science

Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray: Sung Han Kim, Weon Seo Park, Boram Park, Jinsoo Chung, Jae Young Joung, Kang Hyun Lee, Ho Kyung Seo; Cancer Res Treat. 2020;52(1):128-138. Published online June 19, 2019; DOI: https://doi.org/10.4143/crt.2019.119

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry.
Materials and Methods
Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300).
Results
Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05).
Conclusion
Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy.

Citations

Citations to this article as recorded by

A multi‐institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence
Soichiro Shimura, Kazumasa Matsumoto, Masaomi Ikeda, Shigenori Moroo, Dai Koguchi, Yoshinori Taoka, Takahiro Hirayama, Yasukiyo Murakami, Takuji Utsunomiya, Daisuke Matsuda, Norihiko Okuno, Akira Irie, Masatsugu Iwamura
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 71. CrossRef
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, Davide Campobasso, Fabiana Perrone, Michele Maffezzoli, Irene Testi, Luca Isella, Umberto Maestroni, Sebastiano Buti
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma
Luca Campedel, Eva Compérat, Géraldine Cancel‐Tassin, Justine Varinot, Christian Pfister, Clara Delcourt, Françoise Gobet, Mathieu Roumiguié, Pierre‐Marie Patard, Gwendoline Daniel, Pierre Bigot, Julie Carrouget, Caroline Eymerit, Stéphane Larré, Priscill
BJU International.2023; 132(5): 581. CrossRef
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Yi Lu, Jiaqi Kang, Zhiwen Luo, Yuxuan Song, Jia Tian, Zhongjia Li, Xiao Wang, Li Liu, Yongjiao Yang, Xiaoqiang Liu
Frontiers in Oncology.2020;[Epub] CrossRef

7,075 View
141 Download
4 Web of Science
4 Crossref

Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer: Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park; Cancer Res Treat. 2019;51(3):910-918. Published online October 2, 2018; DOI: https://doi.org/10.4143/crt.2018.314

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by

Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
Cancer Medicine.2021; 10(9): 3013. CrossRef

6,156 View
144 Download
1 Web of Science
1 Crossref

Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population: Sung Han Kim, Sohee Kim, Jae Young Joung, Whi-An Kwon, Ho Kyung Seo, Jinsoo Chung, Byung-Ho Nam, Kang Hyun Lee; Cancer Res Treat. 2018;50(4):1194-1202. Published online December 21, 2017; DOI: https://doi.org/10.4143/crt.2017.484

Abstract PDF Supplementary Material PubReader ePub

Purpose
The use of prostate-specific antigen as a biomarker for prostate cancer (PC) has been controversial and is, therefore, not used by many countries in their national health screening programs. The biological characteristics of PC in East Asians including Koreans and Japanese are different from those in the Western populations. Potential lifestyle risk factors for PC were evaluated with the aim of developing a risk prediction model.
Materials and Methods
A total of 1,179,172 Korean men who were cancer free from 1996 to 1997, had taken a physical examination, and completed a lifestyle questionnaire, were enrolled in our study to predict their risk for PC for the next eight years, using the Cox proportional hazards model. The model’s performance was evaluated using the C-statistic and Hosmer‒Lemeshow type chi-square statistics.
Results
The risk prediction model studied age, height, body mass index, glucose levels, family history of cancer, the frequency of meat consumption, alcohol consumption, smoking status, and physical activity, which were all significant risk factors in a univariate analysis. The model performed very well (C statistic, 0.887; 95% confidence interval, 0.879 to 0.895) and estimated an elevated PC risk in patients who did not consume alcohol or smoke, compared to heavy alcohol consumers (hazard ratio [HR], 0.78) and current smokers (HR, 0.73) (p < 0.001).
Conclusion
This model can be used for identifying Korean and other East Asian men who are at a high risk for developing PC, as well as for cancer screening and developing preventive health strategies.

Citations

Citations to this article as recorded by

To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis, Nikolaos Sofikitis
Cancers.2024; 16(20): 3453. CrossRef
Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study
Tao Thi Tran, Jeonghee Lee, Junetae Kim, Sun-Young Kim, Hyunsoon Cho, Jeongseon Kim
BMC Public Health.2024;[Epub] CrossRef
Combinations of lifestyle behaviors and cancer risk among Korean adults
Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
Scientific Reports.2023;[Epub] CrossRef
Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies
Sarah Al-Fayez, Ashraf El-Metwally
Tobacco Induced Diseases.2023; 21(February): 1. CrossRef
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Taewon Hwang, Hyungseok Oh, Jung Ah Lee, Eo Jin Kim
BMC Urology.2023;[Epub] CrossRef
Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
Saeedeh Nouri-Majd, Asma Salari-Moghaddam, Azadeh Aminianfar, Bagher Larijani, Ahmad Esmaillzadeh
Frontiers in Nutrition.2022;[Epub] CrossRef
Alcohol and Prostate Cancer: Time to Draw Conclusions
Amanda J. Macke, Armen Petrosyan
Biomolecules.2022; 12(3): 375. CrossRef
Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
Yan Jin, Jae Hung Jung, Woong Kyu Han, Eu Chang Hwang, Yoonmi Nho, Narae Lee, Ji Eun Yun, Kwang Suk Lee, Sang Hyub Lee, Hakmin Lee, Su-Yeon Yu
Investigative and Clinical Urology.2022; 63(3): 251. CrossRef
Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
Korean Journal of Community Nutrition.2021; 26(3): 211. CrossRef
Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review
Antonio Bandala-Jacques, Kevin Daniel Castellanos Esquivel, Fernanda Pérez-Hurtado, Cristobal Hernández-Silva, Nancy Reynoso-Noverón
JMIR Cancer.2021; 7(3): e30430. CrossRef
Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
Journal of Personalized Medicine.2021; 12(1): 2. CrossRef
Lifestyles, health habits, and prostate cancer
Tomoyuki Kawada
Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1623. CrossRef
Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
Okyaz Eminaga, Omran Al-Hamad, Martin Boegemann, Bernhard Breil, Axel Semjonow
Health Informatics Journal.2020; 26(2): 945. CrossRef
Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen
Sachin Mishra, Eun-Seong Kim, Parshant Kumar Sharma, Zhi-Ji Wang, Sung-Hyun Yang, Ajeet Kumar Kaushik, Cong Wang, Yang Li, Nam-Young Kim
ACS Applied Bio Materials.2020; 3(11): 7821. CrossRef
A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age
Hye Sim Kim, Tae Hwa Go, Dae Ryong Kang, Jae Hung Jung, Sung Won Kwon, Sae Chul Kim, Jae Mann Song, Hyun Chul Chung, Sang Baek Koh
Journal of Health Informatics and Statistics.2019; 44(4): 410. CrossRef

10,114 View
258 Download
13 Web of Science
15 Crossref

Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study: Jae Young Joung, Whi-An Kwon, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won; Cancer Res Treat. 2018;50(1):293-301. Published online April 19, 2017; DOI: https://doi.org/10.4143/crt.2016.543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Secondary primary cancers (SPCs) commonly arise in patients with renal cell carcinoma (RCC). We designed the present study to estimate the SPC incidence in Korean patients with RCC.
Materials and Methods
The study cohort was population-based and consisted of 40,347 individuals from the Korean Central Cancer Registry who were diagnosed with primary renal cancer between 1993 and 2013. Standardized incidence ratios (SIRs) for SPCs were estimated for different ages at diagnosis, latencies, diagnostic periods, and treatments.
Results
For patients with primary RCC, the risk of developing a SPC was higher than the risk of developing cancer in the general population (SIR, 1.13; 95% confidence interval, 1.08 to 1.18). Most cancer types showed higher incidences in patients with RCC than in the general population. However, the relative incidence of gastric cancer as an SPC varied by age. Gastric cancer incidence was elevated in young patients (< 30 years) with RCC, but reduced in older (≥ 30) patients with RCC. Patients with advanced RCC died prematurely, regardless of SPC development. In contrast, those with early-stage RCC survived for longer periods, although SPC development affected their post-RCC survival. After SPC development, women had better survival than men.
Conclusion
In Korean patients with primary RCC, the incidence of SPC was 13% higher than the incidence of cancer in the general population. These findings may play important roles in the conduct of follow-up evaluations and education for patients with RCC.

Citations

Citations to this article as recorded by

Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report
Shiying Tang, Yixiao Deng, Yinan Yan, Jie Bai, Huiying He, Shudong Zhang, Jie Yang, Min Qiu, Xiaojun Tian
Current Urology.2024;[Epub] CrossRef
Renal cell carcinoma and risk of second primary cancer: A Danish nationwide cohort study
Maria B. Bengtsen, Dóra K. Farkas, Henrik T. Sørensen, Mette Nørgaard
Cancer Medicine.2024;[Epub] CrossRef
Chance, ignorance, and the paradoxes of cancer: Richard Peto on developing preventative strategies under uncertainty
George Davey Smith, Albert Hofman, Paul Brennan
European Journal of Epidemiology.2023; 38(12): 1227. CrossRef
Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
Frontiers in Surgery.2022;[Epub] CrossRef
Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database
Hong Liu, Xin Heng, Yuan Tian, Zhongming Yang
Scientific Reports.2022;[Epub] CrossRef
Being Precise About Precision Mental Health
Peter Szatmari, Ezra Susser
JAMA Psychiatry.2022; 79(12): 1149. CrossRef
Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Tianhui Chen, Asta Försti, Otto Hemminki, Kari Hemminki
European Urology Open Science.2021; 24: 52. CrossRef
miR‐34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis
Huaiguo Wu, Xike Zhou, Xuedong Wang, Wei Cheng, Xinjia Hu, Yueping Wang, Bing Luo, Wenjun Huang, Juan Gu
Journal of Cellular and Molecular Medicine.2021; 25(4): 1896. CrossRef
Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk?
Lily N. Trinh, Andrew R. Crawford, Mohammad H. Hussein, Mourad Zerfaoui, Eman A. Toraih, Gregory W. Randolph, Emad Kandil
Cancers.2021; 13(6): 1402. CrossRef
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova, Ladislav Dusek
Cancer Epidemiology.2021; 72: 101929. CrossRef
Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data
Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi
Radiation Oncology Journal.2021; 39(2): 107. CrossRef
The Risk and Prognosis of Secondary Primary Malignancy in Lung Cancer: A Population-Based Study
Jia Hong, Rongrong Wei, Chuang Nie, Anastasiia Leonteva, Xu Han, Xinyu Du, Jing Wang, Lin Zhu, Wenjing Tian, Haibo Zhou
Future Oncology.2021; 17(33): 4497. CrossRef
Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy
Xi Tian, Wen-Hao Xu, Jun-Long Wu, Hua-Lei Gan, Hong-Kai Wang, Wei-Jie Gu, Yuan-Yuan Qu, Hai-Liang Zhang, Ding-Wei Ye
Pathology and Oncology Research.2021;[Epub] CrossRef
Primary Adenocarcinoma of Lung with Synchronous Renal Cell Carcinoma: A Case Report and Review of the Literature
Sharareh Seifi, Zahra Esfahani-Monfared, Mihan Pourabdollah, Sara Haseli
International Journal of Cancer Management.2020;[Epub] CrossRef
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry
Seung-Ki Min, Sung Weon Choi, Jiwon Lim, Joo Yong Park, Kyu-Won Jung, Young-Joo Won
Oral Oncology.2019; 95: 16. CrossRef
Post–Modern Epidemiology: When Methods Meet Matter
George Davey Smith
American Journal of Epidemiology.2019; 188(8): 1410. CrossRef
Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis
Mierxiati Abudurexiti, Jun Wang, Ning Shao, Fang-Ning Wan, Wen-Kai Zhu, Bo Dai, Yao Zhu, Ding-Wei Ye
SN Comprehensive Clinical Medicine.2019; 1(11): 900. CrossRef
Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
BMC Cancer.2018;[Epub] CrossRef

11,579 View
267 Download
18 Web of Science
18 Crossref

Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea: Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Hyunsoon Cho, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won; Cancer Res Treat. 2017;49(3):607-615. Published online September 23, 2016; DOI: https://doi.org/10.4143/crt.2016.139

Abstract PDF Supplementary Material PubReader ePub

Purpose
This descriptive study assessed the current trends in the incidence of urological cancers and patient survival in Korea.
Materials and Methods
In this nationwide retrospective observational study based on the data from the Korea National Cancer Incidence Database (KNCIDB), this study analyzed the age-standardized incidence rates (ASRs) and annual percentage changes (APCs) of kidney, bladder, prostate, testicular, and penile cancers as well as cancer of the renal pelvis and ureter between 1999 and 2012. The relative survival rates (RSRs) were calculated for urological cancer patients diagnosed between 1993 and 2012 from the KNCIDB data.
Results
Prostate cancer was diagnosed in 66,812 individuals followed by bladder (41,549) and kidney (36,836) cancers. The overall ASR (18.26 per 100,000) increased with age because of the higher ASRs of bladder and prostate cancers in the elderly. The ASR for kidney cancer was highest in the 40-59-year-old group, whereas testicular cancer occurred most frequently before the age of 40. The incidence of most urological cancers increased (overall APC, 6.39%; p < 0.001), except for penile (APC, –2.01%; p=0.05) and bladder (APC, –0.40%; p=0.25) cancers. The overall survival increased steadily (5-year RSR, 66.4% in 1993-1995 vs. 84.2% in 2008-2012; p < 0.001), particularly for prostate (by 34.10%) and kidney (by 16.30%) cancers, but not for renal pelvis and ureter cancers (–7.20%).
Conclusion
The most common urological cancer in Korea was prostate cancer followed by bladder and kidney cancers. The incidence of most urological cancers, except for penile and bladder cancers, increased. Survival also increased, particularly for prostate and kidney cancers.

Citations

Citations to this article as recorded by

Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020
Seunghyeon Cho, Won-Ju Park
Investigative and Clinical Urology.2024; 65(1): 23. CrossRef
Risk Factors Associated with Urothelial Bladder Cancer
Souhail Alouini
International Journal of Environmental Research and Public Health.2024; 21(7): 954. CrossRef
Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
BMC Cancer.2023;[Epub] CrossRef
Empowerment-Based Education in Urological Patients: A Scoping Review
Giulia Villa, Emanuele Galli, Vittoria Azzimonti, Marianna Doneda, Noemi Giannetta, Duilio Fiorenzo Manara
Clinical Nursing Research.2022; 31(4): 666. CrossRef
Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
Investigative and Clinical Urology.2022; 63(2): 175. CrossRef
MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?
Alessandra Cinque, Anna Capasso, Riccardo Vago, Matteo Floris, Michael W. Lee, Roberto Minnei, Francesco Trevisani
International Journal of Molecular Sciences.2022; 23(5): 2602. CrossRef
Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
Minsu Choi, Teak Jun Shin, Byung Hoon Kim, Chun Il Kim, Kyung Seop Lee, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Tae Gyun Kwon, Young Hwii Ko, Yoon Soo Hah, Jae-Shin Park, Se Yun Kwon
The Korean Journal of Urological Oncology.2022; 20(2): 115. CrossRef
The association between pain intensity and disability in patients with failed back surgery syndrome, treated with spinal cord stimulation
Mats De Jaeger, Lisa Goudman, Sam Eldabe, Robert Van Dongen, Ann De Smedt, Maarten Moens
Disability and Rehabilitation.2021; 43(15): 2157. CrossRef
Rapid recurrence of squamous cell carcinoma at a lymphocele after nephroureterectomy: A rare case report
Kosuke Ogawa, Yousuke Shimizu, Shoko Uketa, Noriaki Utsunomiya, Satsuki Asai, Misa Ishihara, Kimio Hashimoto, Sojun Kanamaru
IJU Case Reports.2021; 4(2): 118. CrossRef
Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry
Mohd Nasrullah Nik Ab Kadir, Suhaily Mohd Hairon, Najib Majdi Yaacob, Azizah Ab Manan, Nabihah Ali
International Journal of Environmental Research and Public Health.2021; 18(10): 5237. CrossRef
The incidence and prevalence of upper tract urothelial carcinoma: a systematic review
Ahmed Soualhi, Elke Rammant, Gincy George, Beth Russell, Deborah Enting, Rajesh Nair, Mieke Van Hemelrijck, Cecilia Bosco
BMC Urology.2021;[Epub] CrossRef
Impact of chemotherapy on subsequent generations
Biren V. Patel, James M. Hotaling
Urologic Oncology: Seminars and Original Investigations.2020; 38(1): 10. CrossRef
Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country
Chuo Yew Ting, Guan Chou Teh, Kong Leong Yu, Haridah Alias, Hui Meng Tan, Li Ping Wong
Supportive Care in Cancer.2020; 28(4): 1703. CrossRef
Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
Cancer Research and Treatment.2020; 52(1): 301. CrossRef
Anesthetic considerations for urologic surgeries
Chang-Hoon Koo, Jung-Hee Ryu
Korean Journal of Anesthesiology.2020; 73(2): 92. CrossRef
Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes
Sungmin Woo, Jad Bou Ayache, Peter Sawan, Julian Infantino, Natalie Gangai, Andreas Wibmer, Hedvig Hricak, Jeffrey S. Groeger, Hebert Alberto Vargas
Emergency Radiology.2020; 27(4): 413. CrossRef
Detection of Incidental Prostate Cancer or Urothelial Carcinoma Extension in Urinary Bladder Cancer Patients by Using Multiparametric MRI: A Retrospective Study Using Prostate Imaging Reporting and Data System Version 2.0
Sang Eun Yoon, Byung Chul Kang, Hyun-Hae Cho, Sanghui Park
Journal of the Korean Society of Radiology.2020; 81(3): 610. CrossRef
Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population
Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
Cancer Research and Treatment.2019; 51(1): 289. CrossRef
Synchronous Bilateral RCC Is Associated With Poor Recurrence-Free Survival Compared With Unilateral RCC: A Single-Center Study With Propensity Score Matching Analysis
Jung Kwon Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
Clinical Genitourinary Cancer.2019; 17(3): e570. CrossRef
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using th
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung
Cancer Research and Treatment.2019; 51(2): 758. CrossRef
Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015
Ho Won Kang, Sung Pil Seo, Won Tae Kim, Seok Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Seok-Soo Byun, Yong-June Kim
Investigative and Clinical Urology.2019; 60(3): 184. CrossRef
Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung‐Hoo Hong, Jae Young Park, Jinsoo Chung
Cancer Medicine.2019; 8(7): 3401. CrossRef
The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma
Bohyun Kim, Minsun Jung, Kyung Chul Moon
Disease Markers.2019; 2019: 1. CrossRef
History of Diabetes Mellitus and Risk of Prostate Cancer: A Meta-Epidemiological Study of Population-Based Cohort Studies in East Asian Men
Jong-Myon Bae
The Korean Journal of Urological Oncology.2019; 17(3): 119. CrossRef
Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24
Jinsung Park, Dong Wook Shin, Tae-Hwan Kim, Seung Il Jung, Jong Kil Nam, Seung Chol Park, Sungwoo Hong, Jae Hung Jung, Hongwook Kim, Won Tae Kim
Cancer Research and Treatment.2018; 50(1): 40. CrossRef
Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor
Byung Soo Kim, Bum Sik Tae, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Investigative and Clinical Urology.2018; 59(1): 10. CrossRef
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
Investigative and Clinical Urology.2018; 59(2): 98. CrossRef
Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma
Jae Won Joung, Hoon Kyu Oh, Sun Jae Lee, Young Ah Kim, Hyun Jin Jung
Journal of Pathology and Translational Medicine.2018; 52(5): 323. CrossRef
Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma
Myung-Giun Noh, Sung Sun Kim, Eu Chang Hwang, Dong Deuk Kwon, Chan Choi
Journal of Pathology and Translational Medicine.2017; 51(4): 365. CrossRef

12,691 View
264 Download
24 Web of Science
29 Crossref

Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy: Sung Han Kim, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung; Cancer Res Treat. 2016;48(3):1092-1101. Published online January 28, 2016; DOI: https://doi.org/10.4143/crt.2015.316

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare the outcomes of first-line systemic targeted therapy (TT) and immunotherapy (IT) in patients with metastatic renal cell carcinoma (mRCC).
Materials and Methods
This study was a retrospective review of the data of 262 patients treated with systemic IT or TT with tyrosine kinase inhibitors between 2003 and 2013. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed using Response Evaluation Criteria in Solid Tumor ver. 1.0 criteria and the Kaplan-Meier method with log-rank test.
Results
During the median 4.3-month treatment and the 24-month follow-up period, the ORR/PFS/OS of the overall first-line and second-line therapy were 41.9%/8.1 months/16.8 months and 27.5%/6.5 months/15.3 months, respectively. The first-line TT/IT/sequential IT had a PFS of 9.3/6.4/5.7 months and an OS of 15.8/16.5/40.6 months (all p < 0.05). The second-line of TT/IT had a PFS of 7.1/2.1 months (both p < 0.05) and an OS of 16.6/8.6 months (p=0.636), respectively. Pazopanib provided the best median PFS of 11.0 months (p < 0.001) and a quadruple IT regimen had a superior PFS (p=0.522). For OS, sequential treatment with IT and TT was superior compared to treatment with either IT or TT alone (40.6/16.5/15.8 months, p=0.014). The prognosis according to the Memorial Sloan Kettering Cancer Center model showed that favorable/intermediate/poor risk groups had a PFS of 8.5/10.4/2.3 months, and an OS of 43.1/20.4/5.6 months, respectively. The prognosis calculated using the Heng model showed that the favorable/intermediate/poor risk groups had a PFS of 9.2/3.9/2.7 months, and an OS of 32.4/16.5/6.1months, respectively (all p < 0.001).
Conclusion
In patients with mRCC, TT provided a better PFS and OS compared with IT.

Citations

Citations to this article as recorded by

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
BMC Cancer.2023;[Epub] CrossRef
Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity
Jiage Ding, Nan Jiang, Yanyan Zheng, Jiawei Wang, Lin Fang, Huizhong Li, Jie Yang, Ankang Hu, Pengli Xiao, Qing Zhang, Dafei Chai, Junnian Zheng, Gang Wang
Pharmacological Research.2022; 175: 106034. CrossRef
Skeletal Muscle Metastasis From Renal Cell Carcinoma: A Case Series and Literature Review
Juan Sun, Zimu Zhang, Yu Xiao, Hanzhong Li, Zhigang Ji, Penghu Lian, Xuebin Zhang
Frontiers in Surgery.2022;[Epub] CrossRef
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Margaret F. Meagher, Maria C Mir, Riccardo Autorino, Andrea Minervini, Maximilian Kriegmair, Tobias Maurer, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Mireia Musquera, Eduard Roussel, Nicola Pavan, Alessandro Antonelli, Shudo
Clinical Genitourinary Cancer.2022; 20(4): 326. CrossRef
Comparison of prognostic factors that affect the survival of patients with metachronous and synchronous metastases of renal cell carcinoma
D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, S. G. Grigoriev, Yu. S. Korneva
Urology Herald.2022; 10(3): 65. CrossRef
Co‐immunization with L‐Myc enhances CD8+ or CD103+ DCs mediated tumor‐specific multi‐functional CD8+ T cell responses
Dafei Chai, Zichun Zhang, Nan Jiang, Jiage Ding, Dong Qiu, Shang Yuchen Shi, Gang Wang, Lin Fang, Huizhong Li, Hui Tian, Jie Yang, Qing Zhang, Junnian Zheng
Cancer Science.2021; 112(9): 3469. CrossRef
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
Sung Han Kim, Dong-Eun Lee, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Investigative and Clinical Urology.2020; 61(2): 146. CrossRef
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
Qian-Kun Yang, Tong Chen, Shi-Qi Wang, Xiao-Jing Zhang, Zhong-Xiang Yao
Angiogenesis.2020; 23(3): 279. CrossRef
Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis
Stefania Brozzetti, Simone Bini, Nelide De Lio, Carlo Lombardo, Ugo Boggi
BMC Surgery.2020;[Epub] CrossRef
Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy
Sung Han Kim, Jung Kwon Kim, Eun Young Park, Jungnam Joo, Kang Hyun Lee, Ho Kyung Seo, Jae Young Joung, Jinsoo Chung, Aamir Ahmad
PLOS ONE.2019; 14(2): e0211105. CrossRef
A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma
Sung Han Kim, Weon Seo Park, Boram Park, Sahyun Pak, Jinsoo Chung
Frontiers in Oncology.2019;[Epub] CrossRef
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis
Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
BMC Cancer.2019;[Epub] CrossRef
Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis
Sung Han Kim, Kyung-Chae Jeong, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Scientific Reports.2018;[Epub] CrossRef
The effect of a gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced gene expression in renal carcinoma
Lingang Cui, Qingjun Meng, Jianguo Wen, Zechen Yan, Zhan Gao, Yudong Tian, Pengchao Xu, Pengchao Lian, Haizhou Yu
The Journal of Biochemistry.2018; 164(4): 285. CrossRef
The Experience of Uncertainty in Cancer Patients Undergoing Chemotherapy
Yoon Sun Kim, Young Sook Tae, Keum Hee Nam, Heui Yeoung Kim
Asian Oncology Nursing.2018; 18(3): 115. CrossRef
Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity inVHL-deficient human renal cell carcinoma
Susan E. Scanlon, Denise C. Hegan, Parker L. Sulkowski, Peter M. Glazer
Oncotarget.2018; 9(4): 4647. CrossRef
Uncharacteristic metastasis of a renal clear-cell carcinoma to the muscles of the forearm—case report
Oliwia Kozak, Paweł Turzyński, Karolina Markiet, Joanna Pieńkowska, Katarzyna Skrobisz-Balandowska, Michał Studniarek
BJR|case reports.2017; 3(3): 20150495. CrossRef
LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma
Kefeng Wang, Wei Jin, Yan Song, Xiang Fei
Molecular Cancer.2017;[Epub] CrossRef
Anti-angiogenesis target therapy for advanced osteosarcoma
Lu Xie, Tao Ji, Wei Guo
Oncology Reports.2017; 38(2): 625. CrossRef
A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy
Sung Han Kim, Yoon Seok Suh, Dong-Eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Oncotarget.2017; 8(55): 93633. CrossRef
Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison
Sung Han Kim, Yoon Seok Suh, Jung Kwon Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Oncotarget.2017; 8(59): 100056. CrossRef
Introducing, OncoTarget
Mikhail Blagosklonny, Andrei Gudkov
Oncotarget.2010; 1(1): 2. CrossRef
Introducing, OncoTarget
Mikhail Blagosklonny, Andrei Gudkov
Oncotarget.2010; 1(1): 2. CrossRef

11,874 View
171 Download
22 Web of Science
23 Crossref

Case Report

A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review: Sung Han Kim, Heong Dong Yuk, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung; Cancer Res Treat. 2016;48(2):838-842. Published online February 13, 2015; DOI: https://doi.org/10.4143/crt.2014.219

Abstract PDF PubReader ePub

Mucinous cystadenocarcinoma (MC) of the kidney is a rare epithelial tumor originating from the renal pelvic urothelium and few study cases have been reported. Because of the rarity of these tumors and their unknown histogenesis, its diagnosis is difficult until surgical exploration. We report here on a 55-year-old man referred to the urology department from the hepatology department because of a cystic renal mass measuring approximately 5 cm in size, which was detected incidentally under ultrasonography during the routine examination of liver. The renal mass was finally diagnosed as MC originating from kidney after partial nephrectomy and the patient still showed no evidence of recurrence until 12 months postoperatively. This is the first report on a case of renal MC in a patient who underwent partial nephrectomy. The aim of this report is to present our unusual case of MC and also review the previous literature on the pathological and radiological aspects of MC of kidney.

Citations

Citations to this article as recorded by

Mucinous adenocarcinoma in kidneys with developmental anomalies - a report of two cases
Kasi Viswanath Gali, Arun Chawla, K. R. Surag, Sunil Pillai Bhaskara, Padmaraj Hegde
BMC Urology.2024;[Epub] CrossRef
Case report and literature review: Robot-assisted laparoscopic left renal mucinous cystadenocarcinoma radical nephrectomy
Zikuan Ning, Haoxun Zhang, Bowen Wang, Yingwei Wang, Yiwen Liu, Boju Tao, Guoling Zhang, Hua Liu, Chunyang Wang
Frontiers in Surgery.2023;[Epub] CrossRef
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review
An Tamsin, Charlotte Schillebeeckx, Charlotte Van Langenhove, Kathy Vander Eeckt, Dieter Ost, Kevin Wetzels
Acta Chirurgica Belgica.2020; 120(6): 417. CrossRef

24,100 View
119 Download
6 Web of Science
3 Crossref

Original Article

Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis: In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee; Cancer Res Treat. 2010;42(3):157-162. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.157

Abstract PDF PubReader ePub

Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by

Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
European Urology Open Science.2024; 69: 112. CrossRef
Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
Head and Neck Pathology.2024;[Epub] CrossRef
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
Cancers.2021; 14(1): 51. CrossRef
miR-205: A Potential Biomedicine for Cancer Therapy
Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Cells.2020; 9(9): 1957. CrossRef
Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
Oral Diseases.2019; 25(4): 1158. CrossRef
Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
Philipp Wolf
Frontiers in Oncology.2019;[Epub] CrossRef
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
The Aging Male.2018; 21(3): 211. CrossRef
Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
World Journal of Surgical Oncology.2018;[Epub] CrossRef
The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
Medicine.2018; 97(49): e13537. CrossRef
Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
Revista Mexicana de Urología.2016; 76(5): 288. CrossRef
Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
International Journal of Oncology.2014; 44(1): 195. CrossRef
MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
International Journal of Oncology.2013; 43(1): 307. CrossRef

9,207 View
61 Download
12 Crossref

First
Prev
Page of 1
Next
Last

Search